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1269precedence now are the following objectives: 1) a
“culture” change in practice and research, conducive
to distancing ourselves from the attachment and the
“false security” provided by the New York Heart
Association functional classiﬁcation I to IV, A to D
staging and LVEF, when phenotyping our HF
patients, and adopting more liberal classiﬁcation
schemes; and 2) application in research of cluster
analysis to existing data from previously published
randomized HF clinical trials, and data from elec-
tronic medical records, modeled after the present
study (1), in an attempt to come up with winning sets
of a few clusters that will outperform our current HF
classiﬁcation systems. These 2 objectives will pave
the way to a future when design of “rational” clinical
trials (2) will be feasible and cost-effective.*John E. Madias, MD
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Clinical Phenotypes of
Heart Failure SyndromeThe paper by Ahmad et al. (1) used cluster analysis to
describe clinical phenotypes in chronic heart failure
(HF) and identiﬁed 4 “phenotypically distinct and
clinically meaningful groups.” Their cluster analysis
was based on 45 clinical variables and therapeutic
effects from 1,619 patients of the HF-ACTION (Heart
Failure: A Controlled Trial Investigating Outcomes
of Exercise Training) study (2), which evaluated
the effect of exercise training on morbidity and
mortality in patients with chronic systolic HF.
Ahmad et al. (1) named the patient clusters “chronic
heart failure phenotypes” and emphasized “the
high degree of disease heterogeneity” and the
necessity for more precise phenotyping of the HF
syndrome.In our opinion, the cluster analysis of 45 variables
and their grouping in 4 phenotypes is unjustiﬁed
from a pathophysiological point of view. It is rather a
random collection of clinical characteristics with
many of those having a variable degree of life-
threatening signiﬁcance. In contrast to the preced-
ing classiﬁcation, a robust clinical phenotype should
have characteristics that could easily identify an en-
tity with well-deﬁned pathophysiology. The classiﬁ-
cation of the clinical forms of HF in discrete
categories (phenotypes) should recognize the basic
disease process in order to apply the appropriate
treatment. In general, the deﬁnition of a cluster
suggests that there is an internal “togetherness” of
the different clinical characteristics, but the deﬁni-
tion does not imply that 2 particular characteristics in
the same cluster obligatorily have much in common
(3). In reality, the mentioned cardiac symptoms,
signs, and biological elements are nodes with some
associative memory in a vast network of clinical
connections, but they do not form a genuine pheno-
type with discrete pathophysiology.
To explain the molecular, physiological, and
pathological alterations of HF, we should shift
attention to the integrated methodology of systems
biology approach. The nature of the HF syndrome is
characterized by a progressive clinical deterioration
that is explained better with further integration
of data from the ﬁelds of modeling, “omics,” and
complex networks. A new conceptual paradigm of
HF progression needs the construction of novel
models (phenotypes) and clinical networks (clus-
ters) that include the characteristic emergent prop-
erties (signs, symptoms, and biological markers) of
the HF syndrome (4). The human HF syndrome is a
complex entity of mechanistic nature that is inter-
related with 2 adaptive functional regulatory sys-
tems, the remodeling left ventricular procedure
and the homeostatic neurohumoral systems. The
activation of the self-organized positive feedback
stabilization mechanisms of the renin-angiotensin-
aldosterone system, the adrenergic system, and
the natriuretic peptide axis system are important
to strengthen or suppress the cardiac remodeling
procedure.
Francis et al. (5), in an editorial comment regarding
the paper of Ahmad et al. (1), stress the importance of
“pairing phenotypes identiﬁed with cluster analyses
with an ‘omics’ approach.” This is correct, but for
clinical and therapeutic reasons it seems more im-
portant for there to be a meaningful physiolog-
ical relationship between the various components
of “clusters.” With a systems biology approach,
the pathophysiological “interconnection” of the
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1270clustering components, and their integration with
“omics” and with data from genetic and molecular
pathways, are important for the construction of
robust clinical phenotypes. Furthermore, to explain
the functional behavior of cardiac phenotypes,
we should recognize the clinical signiﬁcance of the
regulatory and compensatory role of the remod-
eling myocardial mechanism and of the func-
tional signiﬁcance of the homeostatic neurohumoral
systems.*George E. Louridas, MD, PhD
Katerina G. Lourida, MSc
*Cardiology Clinic, AHEPA Hospital
Aristotle University of Thessaloniki
S. Kiriakidi 1
54636, Thessaloniki
Greece
E-mail: louridasg@gmail.com
http://dx.doi.org/10.1016/j.jacc.2014.12.051
RE F E RENCE S
1. Ahmad T, Pencina MJ, Schulte PJ, et al. Clinical implications of chronic heart
failure phenotypes deﬁned by cluster analysis. J Am Coll Cardiol 2014;64:
1765–74.
2. O’Connor CM, Whellan DJ, Lee KL, et al., for the HF-ACTION In-
vestigators. Efﬁcacy and safety of exercise training in patients with
chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009;
301:1439–50.
3. Easley D, Kleinberg J. Networks, Crowds and Markets: Reasoning About a
Highly Connected World. New York, NY: Cambridge University Press, 2010:
506.
4. Louridas GE, Lourida KG. A conceptual paradigm of heart failure and sys-
tems biology approach. Int J Cardiol 2012;159:5–13.
5. Francis GS, Cogswell R, Thenappan T. The heterogeneity of heart failure:
will enhanced phenotyping be necessary for future clinical trial success? J Am
Coll Cardiol 2014;64:1775–6.REPLY: Applying Cluster Analysis to
Data of Previously Published Chronic
Heart Failure TrialsWe thank Dr. Madias for his interest in our editorial
(1). We appreciate his thoughtful remarks regarding
the importance of adopting a more liberalized clas-
siﬁcation system for heart failure with reduced
ejection fraction, both in clinical practice as well as
in research. We agree that additional cluster ana-
lyses are needed both from large clinical trials and
electronic health records for better phenotyping of
heart failure with reduced ejection fraction patients.
This is a logical ﬁrst step toward building a new
taxonomy for heart failure with reduced ejection
fraction, which will be pivotal in designing cost-
effective and successful clinical trials in the future.*Gary S. Francis, MD
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Systems Biology and Clinical Phenotypes of
Heart Failure SyndromeWe thank Dr. Madias for his insightful comments
regarding our recent publication in the Journal (1). We
wholeheartedly agree with the assertion that the com-
munity of clinicians and researchers should strive for a
more objective methodology by which to classify the
syndrome of heart failure. This is in agreement with the
recent call by the National Research Council report that
calls for a new taxonomy of disease based on both
clinical and molecular measures in order to provide a
more accurate classiﬁcation of disease, with the ulti-
mate goal of enhancing diagnosis and treatment (2).
Drs. Louridas and Lourida suggest that we should
integrate more pathophysiological information into
clustering algorithms. We agree that this approach
might allow for further reﬁnement in phenotyping of
heart failure and would suggest that future studies
include biomarkers representing diverse biological
pathways to encompass the complex biology of heart
failure to the greatest extent possible.
Dr. White articulated the need for an improved
classiﬁcation of heart failure almost a hundred years
ago (3), prompting the widespread use of measures
such as New York Heart Association class. Countless
therapeutic advances have been anchored in the para-
digm established by existing classiﬁcation schemes
(New York Heart Association class, left ventricular
ejection fraction). However, our understanding of
heart failure has dramatically outpaced these de-
scriptors of the syndrome; integrating biological and
clinical data using advanced analytics has the
